Akebia Therapeutics, Inc.

NasdaqCM:AKBA

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Drugstores & Retail Pharmacies

🌿 Fertilizers

💊 Pharmaceuticals

Location

United States

Market Cap

USD 966.50 M

Share Price

USD 3.68

Avg Daily Volume

5,302,792

Change (1 day)

3.37%

Change (1 year)

291.49%

Change (YTD)

93.68%

Akebia Therapeutics, Inc. Share Price Year-To-Date (YTD) return on June 20, 2025: 93.68%

Akebia Therapeutics, Inc. Share Price Year-To-Date (YTD) return is 93.68% on June 20, 2025. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance. Year-to-Date (YTD) return is is the percentage change in the price of a stock from the start of the calendar year up to the current date, it shows how much the stock has gained or lost since the beginning of the year.

Akebia Therapeutics, Inc. 52-week low Share Price is USD 3.97 on June 20, 2025, which is 7.88% above the current Share Price.
Akebia Therapeutics, Inc. 52-week low Share Price is USD 0.86 on June 20, 2025, which is -76.72% below the current Share Price.
Akebia Therapeutics, Inc. average Share Price for the last 52 weeks is USD 1.90.

Daily

From:

To:

Zoom:

Key data

Date	Share Price Year-To-Date (YTD) return	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)	Price to Sales Ratio (P/S)

NasdaqCM: AKBA

Akebia Therapeutics, Inc.

CEO	Mr. John P. Butler MBA
IPO Date	March 20, 2014
Location	United States
Headquarters	245 First Street
Employees	181
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Drugstores & Retail Pharmacies 🌿 Fertilizers 💊 Pharmaceuticals

Description

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.